Status:

COMPLETED

HeRO Vascular Access Device Bacteremia Study

Lead Sponsor:

Merit Medical Systems, Inc.

Collaborating Sponsors:

Integra Clinical Trial Solutions - statistical analysis

Ross, John, M.D.

Conditions:

Hemodialysis

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to compare the safety and effectiveness of the HeRO Vascular Access Device in access challenged (e.g., catheter-dependent) hemodialysis patients. It is hypothesized the ba...

Eligibility Criteria

Inclusion

  • 21 years of age or older.
  • Male or non-pregnant female.
  • Life expectancy less than 1 year.
  • ESRD on hemodialysis with poor remaining venous access sites for creation of an AV fistula or placement of a graft in the upper extremities.
  • Implant side central venous system that surgeon believes can be accessed with interventional devices and can accommodate the 19 Fr GVAS device.
  • Potential GVAS target brachial artery ≥ 3 mm in diameter determined by any suitable measure.
  • Ability to understand and provide written informed consent.
  • Willing and able to cooperate with follow-up examinations.

Exclusion

  • Documented history of drug abuse within six months prior to enrollment.
  • "Planned" concomitant surgical procedure or previous major surgery within 30 days, excluding vascular access related procedures.
  • Currently being treated with another investigational device or drug.
  • Known bleeding diathesis or hypercoaguable state.
  • Peripheral white blood cell count 1.5 K/mm3 or platelet count 50 K/mm3.
  • Degenerative connective tissue disease, e.g., Marfan's and Ehlers Danlos Syndrome. Subjects with Lupus Erythematosus may be enrolled if receiving no immunosuppressants or low dose prednisone only (\< 10 mg/day orally).
  • Subjects with known or suspected concomitant active bacterial, fungal, viral, or parasitic infection. Subjects with Hepatitis B and/or Hepatitis C may be enrolled. Subjects who are HIV + with CD4 count of \< 200 are excluded. Subjects with bacteremia within the past six (6) weeks must have negative blood cultures one week after completing appropriate antibiotic therapy prior to enrollment.
  • Severe underlying co-morbidity or immediate life-threatening condition.
  • Subjects with any condition which, in the opinion of the investigator, could preclude evaluation of response or completion of follow-up or affect subject safety.
  • Subjects with significant arterial occlusive disease which would preclude safe placement of an upper extremity hemodialysis access.
  • Subjects with history or findings on physical examination suggesting significant arterial insufficiency that could affect patient safety and/or device performance in the extremity planned for use with GVAS (i.e., steal syndrome, hand ischemia, peripheral arterial vascular disease, etc.).
  • Subjects with scheduled kidney transplant within the next 12 months.
  • Subjects with history of superior vena cava syndrome are excluded unless it was induced by previous access (these subjects can be enrolled).
  • Subjects with history of decreased cardiac output with ejection fraction \< 20% and/or NYHA class III or IV. NYHA definitions: Class III - Subjects with marked limitation of activity; they are comfortable only at rest; Class IV - Subjects who should be at complete rest, confined to bed or chair; any physical activity brings on discomfort and symptoms occur at rest.
  • Subjects with history of uncorrected hypotension with systolic blood pressures routinely \< 100 mg Hg.
  • Subjects who currently have a pacemaker or ICD in their central venous system on the same side where the GVAS device would be implanted.

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2007

Estimated Enrollment :

38 Patients enrolled

Trial Details

Trial ID

NCT00889564

Start Date

March 1 2006

End Date

March 1 2007

Last Update

August 8 2017

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

University of Miami / Cedars Medical Center

Miami, Florida, United States, 33125

2

St. Joseph's Hospital

Atlanta, Georgia, United States, 30342

3

Southern Illinois University

Springfield, Illinois, United States, 62702

4

North Memorial Medical Center

Robbinsdale, Minnesota, United States, 55422